7 Citations (Scopus)

Abstract

Clinical trials of nanotechnology medical products present complex risk management challenges that involve many uncertainties and important risk-risk trade-offs. This paper inquires whether the precautionary principle can help to inform risk management approaches to nanomedicine clinical trials. It concludes that prudent precaution may be appropriate for ensuring the safety of such trials, but that the precautionary principle itself, especially in its more extreme forms, does not provide useful guidance for specific safety measures.

Original languageEnglish (US)
Pages (from-to)831-840
Number of pages10
JournalJournal of Law, Medicine and Ethics
Volume40
Issue number4
DOIs
StatePublished - Dec 2012

Fingerprint

Nanomedicine
Risk Management
Clinical Trials
Safety
Nanotechnology
Uncertainty

ASJC Scopus subject areas

  • Health Policy
  • Issues, ethics and legal aspects

Cite this

Prudent Precaution in Clinical Trials of Nanomedicines. / Marchant, Gary; Lindor, Rachel A.

In: Journal of Law, Medicine and Ethics, Vol. 40, No. 4, 12.2012, p. 831-840.

Research output: Contribution to journalArticle

@article{29e4ec93b7c54dc39ba99acbfe5be13f,
title = "Prudent Precaution in Clinical Trials of Nanomedicines",
abstract = "Clinical trials of nanotechnology medical products present complex risk management challenges that involve many uncertainties and important risk-risk trade-offs. This paper inquires whether the precautionary principle can help to inform risk management approaches to nanomedicine clinical trials. It concludes that prudent precaution may be appropriate for ensuring the safety of such trials, but that the precautionary principle itself, especially in its more extreme forms, does not provide useful guidance for specific safety measures.",
author = "Gary Marchant and Lindor, {Rachel A.}",
year = "2012",
month = "12",
doi = "10.1111/j.1748-720X.2012.00711.x",
language = "English (US)",
volume = "40",
pages = "831--840",
journal = "Journal of Law, Medicine and Ethics",
issn = "1073-1105",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Prudent Precaution in Clinical Trials of Nanomedicines

AU - Marchant, Gary

AU - Lindor, Rachel A.

PY - 2012/12

Y1 - 2012/12

N2 - Clinical trials of nanotechnology medical products present complex risk management challenges that involve many uncertainties and important risk-risk trade-offs. This paper inquires whether the precautionary principle can help to inform risk management approaches to nanomedicine clinical trials. It concludes that prudent precaution may be appropriate for ensuring the safety of such trials, but that the precautionary principle itself, especially in its more extreme forms, does not provide useful guidance for specific safety measures.

AB - Clinical trials of nanotechnology medical products present complex risk management challenges that involve many uncertainties and important risk-risk trade-offs. This paper inquires whether the precautionary principle can help to inform risk management approaches to nanomedicine clinical trials. It concludes that prudent precaution may be appropriate for ensuring the safety of such trials, but that the precautionary principle itself, especially in its more extreme forms, does not provide useful guidance for specific safety measures.

UR - http://www.scopus.com/inward/record.url?scp=84872167408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872167408&partnerID=8YFLogxK

U2 - 10.1111/j.1748-720X.2012.00711.x

DO - 10.1111/j.1748-720X.2012.00711.x

M3 - Article

VL - 40

SP - 831

EP - 840

JO - Journal of Law, Medicine and Ethics

JF - Journal of Law, Medicine and Ethics

SN - 1073-1105

IS - 4

ER -